Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine 2-16-1 Sugao Miyamae, Kawasaki, Japan.
Curr Pharm Des. 2010;16(26):2910-7. doi: 10.2174/138161210793176509.
Takotsubo cardiomyopathy was first reported in Japan in 1990. Recently, an increasing number of case reports and reviews of takotsubo cardiomyopathy has been published worldwide, including atypical cases with inverted takotsubo cardiomyopathy or incidental coronary artery disease. To date, there has been no guideline for worldwide consensus on takotsubo cardiomyopathy diagnostic criteria and treatment. Although the exact mechanism of takotsubo cardiomyopathy remains to be elucidated, it has been suggested that catecholamine cardiotoxicity plays a crucial role. Here, we summarize the current case reports and reviews in regard to diagnosis, cardiac biomarkers, electrocardiogram, cardiac imaging, mechanism, treatment and prognosis in order to establish a deeper understanding of this syndrome.
应激性心肌病于 1990 年在日本首次报道。近年来,应激性心肌病的病例报告和综述在全球范围内逐渐增多,包括不典型病例伴反常性应激性心肌病或偶发性冠状动脉疾病。迄今为止,尚无全球共识的应激性心肌病诊断标准和治疗指南。尽管应激性心肌病的确切机制仍有待阐明,但儿茶酚胺的心脏毒性作用被认为起着至关重要的作用。在此,我们对目前关于应激性心肌病的病例报告和综述进行了总结,涉及诊断、心脏生物标志物、心电图、心脏影像学、发病机制、治疗和预后,以期加深对该综合征的认识。